All lobbying filings

The McManus Group

The McManus Group filed a Q1 report for Ardelyx on April 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Ardelyx · BioPharma Company

As filed: THE MCMANUS GROUP for ARDELYX.

All filings by The McManus Group · Everything Ardelyx has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to the 2025 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Final Rule (CMS-105-F), specifically the inclusion of oral-only drugs in the ESRD PPS Bundled Payment. H.R.6214 - Kidney Care Access Protection Act Issues related to Most Favored Nation Drug Pricing Reform

Bills named in this filing 1

H.R. 6214
Kidney Care Access Protection Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.